Related Experiment Video
Updated: Aug 2, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Intralesional interferon therapy for basal cell carcinoma
R C Cornell1, H T Greenway, S B Tucker
1Division of Dermatology and Cutaneous Surgery, Scripps Clinic and Research Foundation, La Jolla, CA 92037.
Journal of the American Academy of Dermatology
|October 1, 1990
Summary
Intralesional interferon alfa-2b effectively treated basal cell carcinomas, achieving an 86% cure rate. This treatment offers a promising alternative for patients with noduloulcerative or superficial basal cell carcinomas.
Area of Science:
- Dermatology
- Oncology
- Immunology
Background:
- Basal cell carcinoma (BCC) is the most common type of skin cancer.
- Current treatments for BCC include surgery, radiation, and topical therapies.
- Novel therapeutic approaches are needed for effective BCC management.
Purpose of the Study:
- To evaluate the efficacy and safety of intralesional interferon alfa-2b for treating noduloulcerative and superficial basal cell carcinomas.
Main Methods:
- A randomized clinical trial involving 172 patients across four medical centers.
- Patients received intralesional interferon alfa-2b (1.5 x 10^6 IU) or placebo three times weekly for 3 weeks.
- Treatment efficacy was assessed via biopsy at 16-20 weeks and tumor-free status at 1 year.
Main Results:
- A significantly higher cure rate was observed in the interferon group (86%) compared to placebo (29%) at 16-20 weeks.
- Tumor-free rates at 1 year were 81% for interferon recipients versus 20% for placebo recipients.
- Mild, transient flu-like symptoms were the most common side effects, with only three patients discontinuing treatment.
Conclusions:
- Intralesional interferon alfa-2b demonstrates significant efficacy and a favorable safety profile for treating superficial and noduloulcerative basal cell carcinomas.
- This therapeutic option may be suitable for patients with specific types of basal cell carcinoma.
- Further research could explore interferon alfa-2b in combination therapies or for other skin malignancies.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...